Henry Schein, Inc. $HSIC Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 273,400 shares of the company’s stock after selling 9,004 shares during the period. Rhumbline Advisers owned 0.23% of Henry Schein worth $18,145,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Advisors Asset Management Inc. grew its stake in Henry Schein by 7.7% during the 3rd quarter. Advisors Asset Management Inc. now owns 8,376 shares of the company’s stock valued at $556,000 after purchasing an additional 599 shares in the last quarter. MQS Management LLC acquired a new position in shares of Henry Schein during the third quarter valued at $225,000. SVB Wealth LLC increased its stake in Henry Schein by 3.2% during the 3rd quarter. SVB Wealth LLC now owns 19,991 shares of the company’s stock valued at $1,327,000 after buying an additional 627 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in Henry Schein by 26.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 16,627 shares of the company’s stock worth $1,104,000 after purchasing an additional 3,433 shares in the last quarter. Finally, M.D. Sass LLC lifted its holdings in shares of Henry Schein by 21.3% in the third quarter. M.D. Sass LLC now owns 1,314,603 shares of the company’s stock valued at $87,250,000 after buying an additional 230,407 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Barrington Research set a $79.00 price objective on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Barclays began coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Morgan Stanley boosted their price objective on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Henry Schein has an average rating of “Hold” and a consensus target price of $76.42.

Henry Schein Stock Down 1.3%

NASDAQ:HSIC opened at $77.21 on Wednesday. The firm has a market capitalization of $9.09 billion, a P/E ratio of 24.43, a P/E/G ratio of 2.33 and a beta of 0.88. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.80. The stock’s fifty day simple moving average is $77.25 and its 200-day simple moving average is $71.44. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.